UTI AMC
UTI AMC Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
Not discussed on this call: fundraise, order book.
The short version
UTI AMC targets to manage 2x current AUM by 2031, with current staffing and technology investments supporting this growth. Management refrains from giving specific earnings or profit guidance beyond FY26-27, indicating uncertainty about short-term outlook.
From UTI AMC's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- UTI AMC targets to manage 2x current AUM by 2031, with current staffing and technology investments supporting this growth.
- Q1 FY27 showed strong momentum with quarterly average AUM nearing Rs 4,00,000 crores, a 12.6% YoY industry growth.
- Robust product pipeline includes passive products like UTI Nifty 500 ETF and new active offerings (balanced hybrid, sectoral debt funds).
- Plans to launch SIF and GIFT City outbound funds in H2 FY27 to tap new growth areas.
- Emphasis on expanding SIP franchise and investor reach, adding 3.89 lakh folios and 2.51 lakh new investors in Q1.
- Improved digital capabilities driving 23.93% YoY growth in digital purchase transactions.
- Market share improvements depend on performance turnaround in challenged strategies; current focus on gross sales growth and new product launches.
- Pension fund business expected to see significant workforce expansion to fuel long-term growth.
Profitability & Margins
See what UTI AMC said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Capital Markets
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what UTI AMC said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
UTI AMC — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹390 Cr, net loss ₹51 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What UTI Asset Management Company Ltd's management said in earlier quarters
Others in Capital Markets this season
- Central Depository Services (India) Ltd (Q1 FY27)
The folio count grew by 17% YoY, though unlisted revenue saw a dip; regulatory intent is to increase company participation over time. Key concall takeaways…
- BSE (Q1 FY27)
1.75 lakh crores in fundraising. Key concall takeaways from BSE's Q1 FY27 earnings call — and how it ranks against sector peers.
- National Securities Depository Ltd (Q1 FY27)
Expansion in market penetration, particularly by onboarding new Depository Participants (DPs) including FinTech brokers, which increased from 2% to 20% in…
- Share India Securities Ltd (Q1 FY27)
~470 crores (Q1) to Rs. Key concall takeaways from Share India Sec.'s Q1 FY27 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were UTI AMC Q1 FY27 results?
UTI AMC targets to manage 2x current AUM by 2031, with current staffing and technology investments supporting this growth. Management refrains from giving specific earnings or profit guidance beyond FY26-27, indicating uncertainty about short-term outlook.
What is UTI AMC share price analysis?
UTI AMC currently shows a neutral. The stock trades at a P/E of 21.5 with a market cap of ₹11,479 Cr. Investors should review the full earnings analysis for detailed insights.
Is UTI AMC planning capital expenditure?
UTI AMC is expanding both passive and active investment offerings with new product launches, including UTI Nifty 500 ETF, UTI BSE Index Sector Leaders ETF, balanced hybrid funds, sectoral debt funds, and GIFT City outbound funds planned in H2 FY27.
Keep UTI AMC on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
